Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Vincent Rijckborst, Bettina E. Hansen, Peter Ferenci, Maurizia R. Brunetto, Fehmi Tabak, Yilmaz Cakaloglu, A. Galeota Lanza, Vincenzo Messina, Claudio Iannacone, Benedetta Massetto, Loredana Regep, Massimo Colombo, Harry L A Janssen, Pietro Lampertico

Research output: Contribution to journalArticle

Abstract

Background & Aims: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with

Original languageEnglish
Pages (from-to)1006-1011
Number of pages6
JournalJournal of Hepatology
Volume56
Issue number5
DOIs
Publication statusPublished - May 2012

    Fingerprint

Keywords

  • HBV genotype
  • HBV therapy
  • Immunomodulator
  • Nucleos(t)ide analogues
  • Peginterferon
  • Quantitative HBsAg

ASJC Scopus subject areas

  • Hepatology

Cite this

Rijckborst, V., Hansen, B. E., Ferenci, P., Brunetto, M. R., Tabak, F., Cakaloglu, Y., Lanza, A. G., Messina, V., Iannacone, C., Massetto, B., Regep, L., Colombo, M., Janssen, H. L. A., & Lampertico, P. (2012). Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. Journal of Hepatology, 56(5), 1006-1011. https://doi.org/10.1016/j.jhep.2011.12.007